BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 29717445)

  • 21. [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
    Zhang Y; Xu Y; Wang M
    Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):766-772. PubMed ID: 27866520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating Tumor DNA: Measurement and Clinical Utility.
    Donaldson J; Park BH
    Annu Rev Med; 2018 Jan; 69():223-234. PubMed ID: 28846488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples.
    Chougule A; Basak S
    Indian J Cancer; 2017 Dec; 54(Supplement):S45-S54. PubMed ID: 29292708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients.
    Hur JY; Kim HJ; Lee JS; Choi CM; Lee JC; Jung MK; Pack CG; Lee KY
    Mol Cancer; 2018 Jan; 17(1):15. PubMed ID: 29374476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
    Del Re M; Vasile E; Falcone A; Danesi R; Petrini I
    Expert Rev Mol Diagn; 2014 May; 14(4):453-68. PubMed ID: 24725257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
    Piotrowska Z; Sequist LV
    Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
    Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
    Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.
    Olmedillas-López S; Olivera-Salazar R; García-Arranz M; García-Olmo D
    Mol Diagn Ther; 2022 Jan; 26(1):61-87. PubMed ID: 34773243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Principle and applications of digital PCR.
    Pohl G; Shih IeM
    Expert Rev Mol Diagn; 2004 Jan; 4(1):41-7. PubMed ID: 14711348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.
    Dagogo-Jack I; Saltos A; Shaw AT; Gray JE
    Am Soc Clin Oncol Educ Book; 2017; 37():619-629. PubMed ID: 28561671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.
    Kuang Y; O'Connell A; Sacher AG; Feeney N; Alden RS; Oxnard GR; Paweletz CP
    Methods Mol Biol; 2018; 1768():193-207. PubMed ID: 29717445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A liquid biopsy in primary lung cancer.
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    Surg Today; 2019 Jan; 49(1):1-14. PubMed ID: 29644440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
    Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
    Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring Melanoma Using Circulating Free DNA.
    Diefenbach RJ; Lee JH; Rizos H
    Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.